Certara, Inc. · NASDAQ:CERT
Certara — Q2 2026 Earnings Presentation
16 slides from Certara's earnings presentation, Aug 4, 2026
Slide 1: Second Quarter 2026 Financial Results
Second Quarter 2026 Financial Results August 4, 2026
Slide 2: Disclaimer
Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the “Company,” “Cer
Slide 3: Financial Highlights
Financial Highlights Second Quarter 2026 from Continuing Operations REVENUE NET INCOME ADJ. EBITDA(1) DILUTED EPS ADJUSTED DILUTED EPS(2) $93.3M ($6.1M) $26.2M ($0.04) $0.08 1% change YoY PY $1.5M (3%) YoY change PY $0.01 PY $0.08 (1) See Appendix for reconciliation of net income (loss) to adjusted
Slide 4: 2Q 2026 Results - Revenue
2Q 2026 Results - Revenue GAAP Reported Revenue from Continuing Operations ($Millions) 92.4 93.3 45.7 44.5 46.7 48.8 2Q 2025 2Q 2026 Software Services Certara reported 1% revenue growth during the Second Quarter 4
Slide 5: 2Q 2026 and TTM Results - Net Bookings
2Q 2026 and TTM Results - Net Bookings Excluding the Regulatory and Medical Writing Business 2Q Reported Net Bookings TTM Reported Net Bookings ($Millions) ($Millions) 97.4 98.3 393.9 405.4 50.8 212.0 209.0 47.6 46.6 50.7 181.9 196.4 2Q 2025 2Q 2026 2Q 2025 2Q 2026 Software Services Software Service
Slide 6: Historical TTM Book to Bill
Historical TTM Book to Bill Excluding the Regulatory and Medical Writing Business ($Millions) Book to bill provides forward visibility into revenue growth 6
Slide 7: 2Q 2026 Results – Adjusted EBITDA
2Q 2026 Results – Adjusted EBITDA 2Q Adjusted EBITDA from Continuing Operations(1) ($Millions) 27.0 26.2 2Q 2025 2Q 2026 Adjusted EBITDA 29% 28%(2) Margin(1) 2Q26 Adjusted EBITDA declined (3%) vs. the prior year period (1) See Appendix for a reconciliation net income (loss) to adjusted EBITDA 7 (2)
Slide 8: 2Q26 Business Updates
2Q26 Business Updates Key Takeaways from Second Quarter 2026: Closed Divestiture of 2Q Performance In-Line AI Innovation and Regulatory & Medical Writing with Plan Leadership • Sold business to Veristat for a • Total revenue was in-line with • Collaboration with NVIDIA, consideration of up to $135M.
Slide 9: 2026 Outlook
2026 Outlook FY 2026 guidance for Continuing Operations Key Assumptions REVENUE ADJUSTED ADJUSTED 2026 Guidance EBITDA MARGIN (1) DILUTED EPS(1) $367-$382M 29-31% $0.31-$0.36 Ex-regulatory revenue growth of 0-4% Fully diluted shares expected to be in the range of 155-157M Financial results of the Re
Slide 10: Appendix
Appendix CERTARAQ
Slide 11: Regulatory and Medical Writing – Supplemental Information
Regulatory and Medical Writing – Supplemental Information On April 22nd, 2026, Certara announced it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to $135 million. The transaction closed on May 8th, 2026. Historical R
Slide 12: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2026 2025 2026 2025 (in thousands) Net income (loss) from continuing operations(a) $ (6,081) $ 1,496 $ (17,906) $ 3,001 Interest expense(a) 4,987 4,802 9,928 9,608 Interest income(a) (943) (1
Slide 13: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)
Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2026 2025 2026 2025 ( in thousands) Net income (loss) from continuing operations(a) $ (6,081) $ 1,496 $ (17,906) $ 3,001 Currency (gain) loss(a) 2,358 (577) 2,418 (639) Equity-base
Slide 14: Reconciliation of Diluted EPS to Adjusted Diluted EPS
Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2026 2025 2026 2025 Diluted earnings per share from continuing operations (a) $ (0.04) $ 0.01 $ (0.11) $ 0.02 Currency (gain) loss(a) 0.02 - 0.02 - Equity-based c
Slide 15: Notes to Reconciliations
Notes to Reconciliations a) Represents a measure determined under GAAP. b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation st
Slide 16: Accelerating Medicines, Together
Accelerating Medicines, Together